BioTie Therapies Corp. Interim Report 1 January - 30 September 2012

July - September 2012

* Biotie completed a directed share issue of EUR 20 million to institutional and strategic investors.
* Lundbeck made a EUR 10 Million equity investment in Biotie with a 25% premium and the parties amended the Selincro licensing agreement regarding territories outside the EU and US.

MORE ON THIS TOPIC